{"id":8115,"date":"2015-07-20T00:00:00","date_gmt":"2015-07-19T22:00:00","guid":{"rendered":"https:\/\/idibell.cat\/blog\/2015\/07\/20\/descobreixen-un-peptid-que-inhibeix-la-progressio-tumoral-en-cancer-de-mama\/"},"modified":"2020-05-13T19:47:33","modified_gmt":"2020-05-13T17:47:33","slug":"descobreixen-un-peptid-que-inhibeix-la-progressio-tumoral-en-cancer-de-mama","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2015\/07\/descobreixen-un-peptid-que-inhibeix-la-progressio-tumoral-en-cancer-de-mama\/","title":{"rendered":"Descobreixen un p\u00e8ptid que inhibeix la progressi\u00f3 tumoral en c\u00e0ncer de mama"},"content":{"rendered":"

El c\u00e0ncer de mama \u00e9s una malaltia heterog\u00e8nia que abasta una gran varietat de subtipus, que s\u00f3n cl\u00ednica, morfol\u00f2gica i molecularment diferents. \u00c9s el tumor m\u00e9s freq\u00fcent en dones i, malgrat els aven\u00e7os actuals en el seu diagn\u00f2stic preco\u00e7 i tractament, segueix sent la principal causa de mort en les dones amb c\u00e0ncer. <\/p>\n

El 15% dels casos recentment diagnosticats s\u00f3n c\u00e0ncers de mama triple negatiu, que es defineixen per la seva falta d’expressi\u00f3 de receptors (receptor d’estrogen (ER), receptor de progesterona (PGR) i factor de creixement epid\u00e8rmic hum\u00e0 2 (HER2). Avui dia el c\u00e0ncer de mama triple negatiu \u00e9s probablement una de les \u00e0rees m\u00e9s actives de la investigaci\u00f3 en oncologia a causa de la manca de dianes terap\u00e8utiques i f\u00e0rmacs espec\u00edfics i al relatiu mal pron\u00f2stic de les pacients, especialment aquelles amb malaltia en estadi avan\u00e7at que responen malament a la quimioter\u00e0pia est\u00e0ndard i en les quals el tumor progressa r\u00e0pidament. L’avan\u00e7 en el coneixement d’aquesta malaltia complexa requereix un millor coneixement del seu perfil molecular i el desenvolupament de ter\u00e0pies espec\u00edfiques dirigides a dianes del c\u00e0ncer de mama triple negatiu. <\/p>\n

Investigadors del grup de Gen\u00e8tica Humana de l\u2019IDIBELL en col\u00b7laboraci\u00f3 amb investigadors de l\u2019Institut Catal\u00e0 d\u2019Oncologia, el Centre tecnol\u00f2gic LEITAT i la Universitat de Barcelona han identificat un p\u00e8ptid (seq\u00fc\u00e8ncia d\u2019amino\u00e0cids) derivat de la porte\u00efna RCAN3 anomenat R3178-210<\/sup>. Aquesta mol\u00e8cula inhibeix significativament el creixement tumoral i l\u2019angiog\u00e8nesi (formaci\u00f3 de nous vasos sanguinis que aporten nutrients a les c\u00e8l\u00b7lules tumorals) en un model de ratol\u00ed al qual s\u2019ha implantat un tumor de mama triple negatiu hum\u00e0. Els resultats de l\u2019estudi s\u2019han publicat a la revista Carcinogenesis. <\/p>\n

\u201cEl nostre treball no nom\u00e9s ens ha perm\u00e8s esbrinar nous mecanismes moleculars implicats en la progressi\u00f3 tumoral del c\u00e0ncer de mama\u201d explica la investigadora Merc\u00e8 P\u00e9rez Riba, co-autora de l\u2019estudi,<\/p>\n

\u201csin\u00f3 que mostra que el p\u00e8ptid R3178-210<\/sup> posseeix potents propietats com a supressor tumoral i, a m\u00e9s, \u00e9s una nova eina per al desenvolupament de nous f\u00e0rmacs antitumorals potents i espec\u00edfics\u201d. <\/p>\n

Sergio Mart\u00ednez-H\u00f8yer, S\u00f2nia Sol\u00e9-S\u00e1nchez, Fernando Aguado, Sara Mart\u00ednez-Mart\u00ednez, Eva Serrano-Candelas, Jos\u00e9 Luis Hern\u00e1ndez, Mar Iglesias, Juan Miguel Redondo, Oriol Casanovas, Ramon Messeguer and Merc\u00e8 P\u00e9rez-Riba. A novel role for an RCAN3-derived peptide as a tumor suppressor in breast c\u00e1ncer. <\/strong>Carcinogenesis<\/em>, 2015, 1\u20138. doi:10.1093\/carcin\/bgv056<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Refer\u00e8ncia de l\u2019article A novel role for an RCAN3-derived peptide as a tumor suppressor in breast c\u00e1ncer. doi:10.1093\/carcin\/bgv056<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8115","post","type-post","status-publish","format-standard","hentry","category-sin-categorizar"],"publishpress_future_action":{"enabled":false,"date":"2024-12-30 01:52:07","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=8115"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8115\/revisions"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=8115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=8115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=8115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}